Prof. Andrew Owen is co-director of the Centre of Excellence for Long-acting Therapeutics (CELT), a fellow of the Royal Society of Biology, a fellow of the British Pharmacological Society, a fellow of the Learned Society of Wales and a Trustee for the British Society for Nanomedicine. His clinical and basic research focuses on understanding mechanisms that underpin inter-patient variability in pharmacokinetics and pharmacodynamics. A major emphasis has been to employ knowledge of these mechanisms to accelerate the translation of novel drug delivery technologies. Professor Owen has also been intensively engaged in preclinical and clinical evaluation of SARS-CoV-2 therapeutic candidates during the COVID-19 pandemic and holds several National and International advisory roles in this capacity. He is principal investigator for LONGEVITY which is an international project that aims to translate novel long-acting medicines for malaria chemoprophylaxis, tuberculosis prevention and Hepatitis C Virus therapy. He also leads a modelling core for the NIH-funded Long-acting/Extended-release Antiretroviral resource Program.
